CN116298277A - 一种样本处理液及其应用 - Google Patents
一种样本处理液及其应用 Download PDFInfo
- Publication number
- CN116298277A CN116298277A CN202310358223.4A CN202310358223A CN116298277A CN 116298277 A CN116298277 A CN 116298277A CN 202310358223 A CN202310358223 A CN 202310358223A CN 116298277 A CN116298277 A CN 116298277A
- Authority
- CN
- China
- Prior art keywords
- sample
- base liquid
- sample processing
- final concentration
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 38
- 239000007788 liquid Substances 0.000 claims abstract description 103
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 11
- 238000012545 processing Methods 0.000 claims description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 22
- 159000000003 magnesium salts Chemical class 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 239000013504 Triton X-100 Substances 0.000 claims description 12
- 229920004890 Triton X-100 Polymers 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 11
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- 241000711573 Coronaviridae Species 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 238000003018 immunoassay Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 241000712461 unidentified influenza virus Species 0.000 claims description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- 229920004896 Triton X-405 Polymers 0.000 claims description 4
- 229920001992 poloxamer 407 Polymers 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 2
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 18
- 150000003839 salts Chemical class 0.000 abstract description 3
- 239000002280 amphoteric surfactant Substances 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 90
- 238000001514 detection method Methods 0.000 description 21
- 239000000203 mixture Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000009472 formulation Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000003908 quality control method Methods 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000003317 immunochromatography Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 241000713196 Influenza B virus Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- -1 BB (borate buffer) Chemical compound 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310358223.4A CN116298277A (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310358223.4A CN116298277A (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
| CN202010916312.2A CN111983217B (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010916312.2A Division CN111983217B (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116298277A true CN116298277A (zh) | 2023-06-23 |
Family
ID=73447504
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010916312.2A Active CN111983217B (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
| CN202310358223.4A Pending CN116298277A (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010916312.2A Active CN111983217B (zh) | 2020-09-03 | 2020-09-03 | 一种样本处理液及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN111983217B (fr) |
| WO (1) | WO2022048177A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111983217B (zh) * | 2020-09-03 | 2023-05-02 | 菲鹏生物股份有限公司 | 一种样本处理液及其应用 |
| CN114015806B (zh) * | 2021-10-29 | 2024-01-30 | 杭州金域医学检验所有限公司 | 一种冠状病毒质控品稀释液及其制备方法和应用 |
| CN113985028A (zh) * | 2021-11-25 | 2022-01-28 | 济南百博生物技术股份有限公司 | 一种用于胶体金法抗原检测稀释液 |
| CN114675017A (zh) * | 2022-03-25 | 2022-06-28 | 艾康生物技术(杭州)有限公司 | 一种生物样本提取液及其应用和使用方法 |
| CN115047187A (zh) * | 2022-07-26 | 2022-09-13 | 石家庄希宝生物科技有限公司 | 试纸条样品垫处理液、其制备方法及其应用 |
| CN115951043A (zh) * | 2023-03-09 | 2023-04-11 | 天津博奥赛斯生物科技股份有限公司 | 一种用于新冠抗原胶体金检测的样本处理液 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH095326A (ja) * | 1995-06-22 | 1997-01-10 | Ss Pharmaceut Co Ltd | 金コロイド免疫測定法 |
| US6743597B1 (en) * | 2000-06-13 | 2004-06-01 | Lifescan, Inc. | Compositions containing a urea derivative dye for detecting an analyte and methods for using the same |
| EP3216462A3 (fr) * | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Compositions contenant un anticorps stable |
| JP5567932B2 (ja) * | 2010-08-03 | 2014-08-06 | 田中貴金属工業株式会社 | イムノクロマトグラフィー用試薬組成物およびそれを用いた測定方法 |
| CN103380377B (zh) * | 2011-02-25 | 2016-01-27 | 美迪恩斯生命科技株式会社 | 心肌肌钙蛋白的测定方法 |
| CN102768275A (zh) * | 2012-07-10 | 2012-11-07 | 北京陆桥技术有限责任公司 | 金黄色葡萄球菌肠毒素检测试剂盒及其制备方法和应用 |
| CN105745541B (zh) * | 2013-09-10 | 2019-09-13 | 电化生研株式会社 | 流感病毒免疫测定中的检样处理方法和免疫测定方法 |
| CN105754956B (zh) * | 2016-03-16 | 2020-05-26 | 上海市浦东新区疾病预防控制中心 | 一种用于检测及分离样本的呼吸道病毒的样本前处理液 |
| KR101782859B1 (ko) * | 2016-03-29 | 2017-09-28 | 원광대학교산학협력단 | 양자점-라텍스 비드-인플루엔자 바이러스 항체 복합체를 이용한 인플루엔자 바이러스 검출용 키트 및 이를 이용한 검출 방법 |
| CN106771250B (zh) * | 2017-01-06 | 2018-08-21 | 杭州京北生物科技有限公司 | 一种用于检测哺乳动物莱姆病的荧光素酶免疫共沉淀试剂盒 |
| CN108535490A (zh) * | 2017-03-06 | 2018-09-14 | 苏州和锐生物科技有限公司 | 生物制剂血药浓度检测方法及试剂 |
| CN111321247B (zh) * | 2018-12-17 | 2022-09-30 | 北京亿森宝生物科技有限公司 | 用于鉴别非洲猪瘟病毒、猪瘟野毒株与猪瘟兔化弱毒疫苗株的冻干微孔板、试剂盒及方法 |
| CN110554203B (zh) * | 2019-09-17 | 2022-10-21 | 浙江大学山东工业技术研究院 | 高密度脂蛋白胆固醇测定试纸 |
| CN110907649A (zh) * | 2019-12-23 | 2020-03-24 | 山东莱博生物科技有限公司 | 一种检测短链脂肪酸的试剂盒及其应用 |
| CN111500769A (zh) * | 2020-03-11 | 2020-08-07 | 南京农业大学 | 一种检测SARS-CoV-2核酸的荧光免疫层析方法 |
| CN111426831B (zh) * | 2020-03-24 | 2023-09-15 | 山东康华生物医疗科技股份有限公司 | 一种联合检测2019新型冠状病毒IgM和IgG抗体的试剂盒及其制备方法 |
| CN111337682B (zh) * | 2020-05-18 | 2020-09-08 | 博奥赛斯（天津）生物科技有限公司 | 一种新型冠状病毒IgM/IgG磁微粒化学发光免疫检测试剂盒 |
| CN111537747B (zh) * | 2020-06-10 | 2022-09-02 | 生物岛实验室 | 一种检测人新型冠状病毒IgG抗体的试纸条、试剂盒及其制备方法 |
| CN111537748B (zh) * | 2020-06-10 | 2022-09-02 | 生物岛实验室 | 一种检测人新型冠状病毒IgM抗体的试纸条、试剂盒及其制备方法 |
| CN111983217B (zh) * | 2020-09-03 | 2023-05-02 | 菲鹏生物股份有限公司 | 一种样本处理液及其应用 |
-
2020
- 2020-09-03 CN CN202010916312.2A patent/CN111983217B/zh active Active
- 2020-09-03 CN CN202310358223.4A patent/CN116298277A/zh active Pending
-
2021
- 2021-05-07 WO PCT/CN2021/092090 patent/WO2022048177A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN111983217A (zh) | 2020-11-24 |
| WO2022048177A1 (fr) | 2022-03-10 |
| CN111983217B (zh) | 2023-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111983217B (zh) | 一种样本处理液及其应用 | |
| EP1826562B1 (fr) | Procede de pretraitement d'un echantillon et procede d'immunoessai utilisant celui-ci | |
| CN112730839B (zh) | 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒 | |
| US20110053181A1 (en) | Method for detecting objective substance and kit for detecting objective substance | |
| CN112014575B (zh) | 一种cyfra21-1测定试剂盒及其制备方法 | |
| JP4704662B2 (ja) | 免疫学的ラテックス比濁分析方法及びその試薬 | |
| WO2015037635A1 (fr) | Procédé de traitement d'échantillon pour dosage immunologique d'un virus de la grippe et procédé de dosage immunologique | |
| KR920007686B1 (ko) | 추출 조성물, 테스트 키트 및 이것을 이용해 단순포진 비루스의 항원을 추출하거나 정량하는 방법 | |
| CN108398564B (zh) | 一种抗torch-IgG型抗体谱芯片及其制备方法与TORCH检测的试剂盒 | |
| JP4115728B2 (ja) | フロースルー式検査法用組成物、これを用いたキット及び検査法 | |
| US11768209B2 (en) | Method and reagent for measuring thyroglobulin | |
| JP2019053060A (ja) | Ｂ型肝炎ウイルスコア抗体の免疫測定方法 | |
| JPH03502248A (ja) | アッセイ用水性洗浄液、診断試験キット及び単純ヘルペスウイルスの測定方法 | |
| CN116298297A (zh) | 一种同时检测合胞病毒和新型冠状病毒抗原的胶体金层析试纸条 | |
| EP4386385A1 (fr) | Procédé de dosage immunologique, diluant d'échantillon et kit d'immunochromatographie | |
| EP4206181A1 (fr) | Réactif de détection dont la spécificité est améliorée par inhibition des faux négatifs | |
| CN113281503B (zh) | 一种用于裂解病毒样本的试剂 | |
| CN114414799A (zh) | 新冠病毒检测层析试剂条、试剂盒及其制作方法 | |
| CN109613239B (zh) | A群轮状病毒检测试纸 | |
| CN111208292A (zh) | 肺炎支原体抗体IgM的免疫检测试剂盒、其制备方法及使用方法 | |
| CN111239411A (zh) | 肺炎支原体抗体IgG的免疫检测试剂盒、其制备方法及使用方法 | |
| CN113295862A (zh) | 基于抗原标记物检测新型冠状病毒SARS-CoV-2抗体的试剂盒及方法 | |
| CN114859042B (zh) | 一种鉴别结合突变型抗原的抗体的方法及试剂 | |
| WO2022054822A1 (fr) | Kit de détection dont la spécificité est améliorée par inhibition des faux positifs | |
| US20210199652A1 (en) | Test Kit For Detecting A Plurality Of Analytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |